MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients
MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients
复制标题
DOI：
10.1016/j.leukres.2007.03.028
复制
发表时间：
2007-12-01
影响因子：
2.7
通讯作者：
Sica, Simona
中科院分区：
文献类型：
--
作者：
Chiusolo, Patrizia;Reddiconto, Giovanni;Sica, Simona
近年来，人们研究了参与化疗药物代谢的不同基因多态性对儿童急性淋巴细胞白血病（ALL）的影响。我们评估了C677T和A1298C亚甲基四氢叶酸还原酶（MTHFR）多态性对82例成人ALL患者复发时间和生存率以及对甲氨蝶呤（MTX）毒性的影响。两种多态性的纯合子野生型和变异型患者的无复发生存率和无事件生存率无显著差异。然而，我们观察到677TT变异体与接受MTX维持治疗的ALL患者亚组的生存率之间存在相关性（p = 0.02）。在同一亚组中，我们证实了MTX治疗期间677TT变异体对毒性的作用（p = 0.003）。(C)2007爱思唯尔有限公司保留所有权利。
Recently the influence of polymorphisms of different genes involved in metabolism of chemoterapic agents have been studied especially in childhood acute lymphoblastic leukemia (ALL). We evaluated the influence of C677T and A1298C methylenetetrahydrofolate reductase (MTHFR) polymorphisms on time to relapse and survival and on methotrexate (MTX) toxicity in 82 ALL adult patients. Relapse free survival and event free survival between homozygous wild-type and variant patients in both polymorphisms were not significantly different. However, we observed an association between 677TT variant and survival in a subset of ALL patients homogenously treated with MTX-based maintenance (p = 0.02). In the same subgroup we confirmed the role of 677TT variant on toxicity during MTX treatment (p = 0.003). (C) 2007 Elsevier Ltd. All rights reserved.